Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study

Ines Vaz-Luis ¹, Rebecca A Ottesen ¹, Melissa E Hughes ¹, Rizvan Mamet ¹, Harold J Burstein ¹, Stephen B Edge ¹, Ana M Gonzalez-Angulo ¹, Beverly Moy ¹, Hope S Rugo ¹, Richard L Theriault ¹, Jane C Weeks ¹, Eric P Winer ¹, Nancy U Lin ²

Affiliations

¹ Ines Vaz-Luis, Melissa E. Hughes, Harold J. Burstein, Jane C. Weeks, Eric P. Winer, and Nancy U. Lin, Dana-Farber Cancer Institute; Beverly Moy, Massachusetts General Hospital, Boston, MA; Ines Vaz-Luis, Instituto de Medicina Molecular, Lisbon, Portugal; Rebecca A. Ottesen and Rizvan Mamet, City of Hope, Duarte; Hope S. Rugo, University of California, San Francisco, San Francisco, CA; Stephen B. Edge, Roswell Park Cancer Institute, Buffalo, NY; Stephen B. Edge, Baptist Cancer Center, Memphis, TN; and Ana M. Gonzalez-Angulo and Richard L. Theriault, University of Texas MD Anderson Cancer Center, Houston, TX.
² Ines Vaz-Luis, Melissa E. Hughes, Harold J. Burstein, Jane C. Weeks, Eric P. Winer, and Nancy U. Lin, Dana-Farber Cancer Institute; Beverly Moy, Massachusetts General Hospital, Boston, MA; Ines Vaz-Luis, Instituto de Medicina Molecular, Lisbon, Portugal; Rebecca A. Ottesen and Rizvan Mamet, City of Hope, Duarte; Hope S. Rugo, University of California, San Francisco, San Francisco, CA; Stephen B. Edge, Roswell Park Cancer Institute, Buffalo, NY; Stephen B. Edge, Baptist Cancer Center, Memphis, TN; and Ana M. Gonzalez-Angulo and Richard L. Theriault, University of Texas MD Anderson Cancer Center, Houston, TX. nlin@partners.org.

PMID: 24888816
45 References
56 citations

Abstract

Purpose: Treatment decisions for patients with T1a,bN0M0 breast cancer are challenging. We studied the time trends in use of adjuvant chemotherapy and survival outcomes among these patients.

Patients And Methods: This was a prospective cohort study within the National Comprehensive Cancer Network Database that included 4,113 women with T1a,bN0M0 breast cancer treated between 2000 and 2009. Tumors were grouped by size (T1a, T1b), biologic subtype defined by hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status, and receipt of chemotherapy with or without trastuzumab.

Results: Median follow-up time was 5.5 years. Eight percent of patients with HR-positive/HER2-negative tumors were treated with chemotherapy. Fifty-two percent of those with HER2-positive or HR-negative/HER2-negative breast cancers received chemotherapy, with an increase over the last decade. Survival outcomes diverged by subtype and size, but the 5-year distant relapse-free survival (DRFS) did not exceed 10% in any subgroup. The 5-year DRFS for patients with T1a tumors untreated with chemotherapy ranged from 93% to 98% (n = 49 to 972), and for patients with T1b tumors, it ranged from 90% to 96% (n = 17 to 2,005). Patients with HR-positive/HER2-negative disease had the best DRFS estimates, and patients with HR-negative/HER2-negative tumors had the lowest. In this observational, nonrandomized cohort study, the 5-year DRFS for treated patients with T1a tumors was 100% for all subgroups (n = 12 to 33), and for patients with T1b tumors, it ranged from 94% to 96% (n = 88 to 241).

Conclusion: Women with T1a,b tumors have an excellent prognosis without chemotherapy. Size and tumor subtype may identify patients in whom the rate of recurrence justifies consideration of chemotherapy. These patients represent an optimal group for evaluating less toxic adjuvant regimens to maintain efficacy while minimizing short- and long-term risks.

Other Links

Free PMC article
Full text on Journal of clinical oncology : official journal of the American Society of Clinical Oncology

References
Cited By

References
Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. Clifford A Hudis, William E Barlow, +8 authors, Jo Anne Zujewski. less J Clin Oncol, 2007 May 22; 25(15). PMID: 17513820 Highly Cited.
Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: a cohort from an integrated health care delivery system. Louis Fehrenbacher, Angela M Capra, +3 authors, Laurel A Habel. less J Clin Oncol, 2014 Jun 04; 32(20). PMID: 24888815
NCCN outcomes research database: data collection via the Internet. J C Niland. Oncology (Williston Park), 2001 Feb 24; 14(11A). PMID: 11195402
Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes. B Fisher, J Dignam, +4 authors, N Wolmark. less J Natl Cancer Inst, 2001 Feb 24; 93(2). PMID: 11208880
The full potential of breast cancer screening use to reduce mortality has not yet been realized in the United States. Mario Schootman, Donna Jeffe, Anat Reschke, Rebecca Aft. Breast Cancer Res Treat, 2004 Apr 28; 85(3). PMID: 15111759
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. M E Charlson, P Pompei, K L Ales, C R MacKenzie. J Chronic Dis, 1987 Jan 01; 40(5). PMID: 3558716 Highly Cited.
A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma. P R Rosen, S Groshen, +2 authors, P E Saigo, D W Kinne, S Hellman. less J Clin Oncol, 1989 Mar 01; 7(3). PMID: 2918331 Highly Cited.
Breast cancer treatment and natural history: new insights from results of screening. L Tabár, G Fagerberg, +2 authors, N E Day, S W Duffy, R M Kitchin. less Lancet, 1992 Feb 15; 339(8790). PMID: 1346670
Insights into breast cancer screening of younger women. Evidence from the 14-year follow-up of the Breast Cancer Detection Demonstration Project. C R Smart, W H Hartmann, O H Beahrs, L Garfinkel. Cancer, 1993 Aug 15; 72(4 Suppl). PMID: 8339237
Paclitaxel-induced neuropathy. T J Postma, J B Vermorken, +2 authors, A J Liefting, H M Pinedo, J J Heimans. less Ann Oncol, 1995 May 01; 6(5). PMID: 7669713
Can comorbidity be measured by questionnaire rather than medical record review? J N Katz, L C Chang, +2 authors, O Sangha, A H Fossel, D W Bates. less Med Care, 1996 Jan 01; 34(1). PMID: 8551813 Highly Cited.
Outcomes assessment in the NCCN. J C Weeks. Oncology (Williston Park), 1998 Jan 16; 11(11A). PMID: 9430183
Outcomes assessment in the NCCN: 1998 update. National Comprehensive Cancer Network. J Weeks. Oncology (Williston Park), 1999 Jun 17; 13(5A). PMID: 10370922
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark. less N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335 Highly Cited.
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Lancet, 2005 May 17; 365(9472). PMID: 15894097 Highly Cited.
The effect of tissue fixation and processing on breast cancer size. Bobbi Pritt, Joseph J Tessitore, Donald L Weaver, Hagen Blaszyk. Hum Pathol, 2005 Aug 09; 36(7). PMID: 16084944
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. Martine J Piccart-Gebhart, Marion Procter, +30 authors, Herceptin Adjuvant (HERA) Trial Study Team. less N Engl J Med, 2005 Oct 21; 353(16). PMID: 16236737 Highly Cited.
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. Edward H Romond, Edith A Perez, +22 authors, Norman Wolmark. less N Engl J Med, 2005 Oct 21; 353(16). PMID: 16236738 Highly Cited.
Effect of screening and adjuvant therapy on mortality from breast cancer. Donald A Berry, Kathleen A Cronin, +8 authors, Cancer Intervention and Surveillance Modeling Network (CISNET) Collaborators. less N Engl J Med, 2005 Oct 28; 353(17). PMID: 16251534 Highly Cited.
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. Heikki Joensuu, Pirkko-Liisa Kellokumpu-Lehtinen, +22 authors, FinHer Study Investigators. less N Engl J Med, 2006 Feb 24; 354(8). PMID: 16495393 Highly Cited.
Peripheral neuropathy induced by microtubule-stabilizing agents. James J Lee, Sandra M Swain. J Clin Oncol, 2006 Apr 01; 24(10). PMID: 16575015 Highly Cited. Review.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark. less J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680 Highly Cited.
Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. Michael J Hassett, A James O'Malley, +2 authors, Juliana R Pakes, Joseph P Newhouse, Craig C Earle. less J Natl Cancer Inst, 2006 Aug 17; 98(16). PMID: 16912263 Highly Cited.
Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study. Ines Vaz-Luis, Rebecca A Ottesen, +8 authors, Nancy U Lin. less Breast Cancer Res, 2012 Oct 03; 14(5). PMID: 23025714 Free PMC article.
Treatment trends and factors associated with survival in T1aN0 and T1bN0 breast cancer patients. Timothy Kennedy, Andrew K Stewart, +3 authors, David P Winchester. less Ann Surg Oncol, 2007 Jul 20; 14(10). PMID: 17638060
Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. Emer O Hanrahan, Ana M Gonzalez-Angulo, +4 authors, Vicente Valero. less J Clin Oncol, 2007 Nov 01; 25(31). PMID: 17971593
Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. M Untch, R D Gelber, +26 authors, HERA Study Team. less Ann Oncol, 2008 Feb 26; 19(6). PMID: 18296421
Factors associated with guideline-concordant use of radiotherapy after mastectomy in the national comprehensive cancer network. Rinaa S Punglia, Melissa E Hughes, +6 authors, Jane C Weeks. less Int J Radiat Oncol Biol Phys, 2008 May 13; 72(5). PMID: 18472360 Free PMC article.
Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. Stephen Chia, Brian Norris, +7 authors, Karen Gelmon. less J Clin Oncol, 2008 Nov 13; 26(35). PMID: 19001334
High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. Ana M Gonzalez-Angulo, Jennifer K Litton, +17 authors, Gabriel N Hortobagyi. less J Clin Oncol, 2009 Nov 04; 27(34). PMID: 19884543 Free PMC article. Highly Cited.
Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. Giuseppe Curigliano, Giuseppe Viale, +10 authors, Aron Goldhirsch. less J Clin Oncol, 2009 Nov 04; 27(34). PMID: 19884553
A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (< or = 1 cm) invasive breast cancer: who might be possible candidates for adjuvant treatment? Yeon Hee Park, Seung Tae Kim, +11 authors, Young-Hyuck Im. less Breast Cancer Res Treat, 2009 Dec 04; 119(3). PMID: 19957028
Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. Lesley A Smith, Victoria R Cornelius, +4 authors, Alison Jones. less BMC Cancer, 2010 Jul 01; 10. PMID: 20587042 Free PMC article. Highly Cited. Systematic Review.
Prognosis and outcome of small (<=1 cm), node-negative breast cancer on the basis of hormonal and HER-2 status. Surabhi Amar, Ann E McCullough, +7 authors, Edith A Perez. less Oncologist, 2010 Oct 12; 15(10). PMID: 20930097 Free PMC article.
Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. Edith A Perez, Edward H Romond, +7 authors, Norman Wolmark. less J Clin Oncol, 2011 Jul 20; 29(25). PMID: 21768458 Free PMC article. Highly Cited.
Adjuvant trastuzumab in HER2-positive breast cancer. Dennis Slamon, Wolfgang Eiermann, +21 authors, Breast Cancer International Research Group. less N Engl J Med, 2011 Oct 14; 365(14). PMID: 21991949 Free PMC article. Highly Cited.
Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer. Heather L McArthur, Kathleen M Mahoney, +5 authors, Clifford A Hudis. less Cancer, 2011 Jun 18; 117(24). PMID: 21681735
Implications of HER2 amplification in small, node-negative breast cancers: do Asians differ? Fuh Yong Wong, Connie Siew Poh Yip, Eu Tiong Chua. World J Surg, 2011 Nov 23; 36(2). PMID: 22105650
Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. Erin J Aiello Bowles, Robert Wellman, +13 authors, Pharmacovigilance Study Team. less J Natl Cancer Inst, 2012 Sep 06; 104(17). PMID: 22949432 Free PMC article. Highly Cited.
Does breast cancer tumor size really matter that much? Louise Provencher, Caroline Diorio, +2 authors, Jean-Charles Hogue, Catherine Doyle, Simon Jacob. less Breast, 2012 Jul 28; 21(5). PMID: 22835917
Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. Edward H Romond, Jong-Hyeon Jeong, +18 authors, Norman Wolmark. less J Clin Oncol, 2012 Sep 19; 30(31). PMID: 22987084 Free PMC article. Highly Cited.
Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. Jersey Chen, Jessica B Long, +3 authors, Cary P Gross. less J Am Coll Cardiol, 2012 Nov 20; 60(24). PMID: 23158536 Highly Cited.
Evolving risk of therapy-related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975-2008. Lindsay M Morton, Graça M Dores, +5 authors, Rochelle E Curtis. less Blood, 2013 Feb 16; 121(15). PMID: 23412096 Free PMC article.
Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial. Sandra M Swain, Gong Tang, +17 authors, Norman Wolmark. less J Clin Oncol, 2013 Aug 14; 31(26). PMID: 23940225 Free PMC article.
Duration and toxicity of adjuvant trastuzumab in older patients with early-stage breast cancer: a population-based study. Ines Vaz-Luis, Nancy L Keating, +3 authors, Rachel A Freedman. less J Clin Oncol, 2014 Feb 12; 32(9). PMID: 24516021 Free PMC article.

Citedby
Update on adjuvant chemotherapy for early breast cancer. Murtuza M Rampurwala, Gabrielle B Rocque, Mark E Burkard. Breast Cancer (Auckl), 2014 Oct 23; 8. PMID: 25336961 Free PMC article. Review.
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. Sara M Tolaney, William T Barry, +16 authors, Eric P Winer. less N Engl J Med, 2015 Jan 08; 372(2). PMID: 25564897 Free PMC article. Highly Cited.
[Is the waiver of chemotherapy for small, node-negative breast cancer justified? ]. Marie-Luise Sautter-Bihl, Felix Sedlmayer. Strahlenther Onkol, 2015 Mar 03; 191(1). PMID: 25729794
Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi-institutional study. Ines Vaz-Luis, Melissa E Hughes, +7 authors, Nancy U Lin. less Cancer, 2015 Mar 12; 121(12). PMID: 25757412 Free PMC article.
Treatment of early-stage HER2+ breast cancer-an evolving field. Arlindo R Ferreira, Kamal S Saini, Otto Metzger-Filho. Ecancermedicalscience, 2015 May 02; 9. PMID: 25932047 Free PMC article. Review.
Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials. Ciara C O'Sullivan, Ian Bradbury, +13 authors, Richard D Gelber. less J Clin Oncol, 2015 Jun 24; 33(24). PMID: 26101239 Free PMC article.
Menacalc, a quantitative method of metastasis assessment, as a prognostic marker for axillary node-negative breast cancer. Catherine L Forse, Seema Agarwal, +9 authors, Irene L Andrulis. less BMC Cancer, 2015 Jun 27; 15. PMID: 26112005 Free PMC article.
The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer. Stefania Gori, Alessandro Inno, +33 authors, Luca Boni. less PLoS One, 2015 Sep 05; 10(9). PMID: 26340098 Free PMC article.
SEOM clinical guidelines in early-stage breast cancer 2015. J A Garcia-Saenz, B Bermejo, +7 authors, E Ciruelos. less Clin Transl Oncol, 2015 Oct 27; 17(12). PMID: 26497356 Free PMC article.
Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. Chau Dang, Hao Guo, +17 authors, Sara M Tolaney. less JAMA Oncol, 2015 Nov 06; 2(1). PMID: 26539793 Free PMC article.
Infracentimetric HER-2 positive breast tumours-review of the literature. Danilo da Fonseca Reis Silva, Joana M Ribeiro. Ecancermedicalscience, 2015 Dec 05; 9. PMID: 26635897 Free PMC article. Review.
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. Shaokun Shu, Charles Y Lin, +36 authors, Kornelia Polyak. less Nature, 2016 Jan 07; 529(7586). PMID: 26735014 Free PMC article. Highly Cited.
Biologic subtype is a more important prognostic factor than nodal involvement in patients with stages I and II breast carcinoma. Hyosun Kim, Jihyoung Cho, Sun Young Kwon, Sun Hee Kang. Ann Surg Treat Res, 2016 Jan 23; 90(1). PMID: 26793686 Free PMC article.
Toward precision medicine of breast cancer. Nicolas Carels, Lizânia Borges Spinassé, Tatiana Martins Tilli, Jack Adam Tuszynski. Theor Biol Med Model, 2016 Mar 02; 13. PMID: 26925829 Free PMC article. Review.
Disparities in Use of Human Epidermal Growth Hormone Receptor 2-Targeted Therapy for Early-Stage Breast Cancer. Katherine Reeder-Hayes, Sharon Peacock Hinton, +2 authors, Ke Meng, Lisa A Carey, Stacie B Dusetzina. less J Clin Oncol, 2016 Apr 14; 34(17). PMID: 27069085 Free PMC article.
Selective activity of deguelin identifies therapeutic targets for androgen receptor-positive breast cancer. Andrew J Robles, Shengxin Cai, Robert H Cichewicz, Susan L Mooberry. Breast Cancer Res Treat, 2016 Jun 04; 157(3). PMID: 27255535 Free PMC article.
Maximiscin Induces DNA Damage, Activates DNA Damage Response Pathways, and Has Selective Cytotoxic Activity against a Subtype of Triple-Negative Breast Cancer. Andrew J Robles, Lin Du, Robert H Cichewicz, Susan L Mooberry. J Nat Prod, 2016 Jun 17; 79(7). PMID: 27310425 Free PMC article.
Biologic behavior and long-term outcomes of breast ductal carcinoma in situ with microinvasion. Yan Fang, Jiayi Wu, +9 authors, Li Zhu. less Oncotarget, 2016 Sep 01; 7(39). PMID: 27577080 Free PMC article.
Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer. Karen A Cadoo, Patrick G Morris, +3 authors, Heather L McArthur. less Clin Breast Cancer, 2016 Sep 14; 16(6). PMID: 27622751 Free PMC article.
The impact of doctor-patient communication on patients' perceptions of their risk of breast cancer recurrence. Nancy K Janz, Yun Li, +7 authors, Sarah T Hawley. less Breast Cancer Res Treat, 2016 Dec 13; 161(3). PMID: 27943007 Free PMC article.
Recurrence risk perception and quality of life following treatment of breast cancer. Sarah T Hawley, Nancy K Janz, +8 authors, Steven J Katz. less Breast Cancer Res Treat, 2016 Dec 23; 161(3). PMID: 28004220 Free PMC article.
Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists at the 15th International St. Gallen Breast Cancer Conference (Vienna 2017). Michael Untch, Jens Huober, +18 authors, Cornelia Liedtke. less Geburtshilfe Frauenheilkd, 2017 Aug 05; 77(6). PMID: 28769126 Free PMC article.
Impact of Detection Method and Accompanying Ductal Carcinoma in Situ on Prognosis of T1a,bN0 Breast Cancer. Shih-Che Shen, Shir-Hwa Ueng, +5 authors, Shin-Cheh Chen. less J Cancer, 2017 Aug 19; 8(12). PMID: 28819437 Free PMC article.
Clinicopathological features and survival of early stage breast cancer in northwest China: A population-based retrospective study of 1287 patients. Shuting Li, Xiangtang Wang, +12 authors, Jin Yang. less Thorac Cancer, 2017 Oct 05; 9(1). PMID: 28976077 Free PMC article.
Structure-Activity Relationships of New Natural Product-Based Diaryloxazoles with Selective Activity against Androgen Receptor-Positive Breast Cancer Cells. Andrew J Robles, Shelby McCowen, +5 authors, Susan L Mooberry. less J Med Chem, 2017 Oct 21; 60(22). PMID: 29053266 Free PMC article.
Prognostic role of pretreatment neutrophil to lymphocyte ratio in breast cancer patients: A meta-analysis. Xu Liu, Jing-Kun Qu, +7 authors, Xiao-Yi Duan. less Medicine (Baltimore), 2017 Nov 16; 96(45). PMID: 29137007 Free PMC article.
Exogenous reproductive hormone use in breast cancer survivors and previvors. Ines Vaz-Luis, Ann H Partridge. Nat Rev Clin Oncol, 2018 Jan 24; 15(4). PMID: 29358778 Review.
The effect of adjuvant chemotherapy on survival in Korean patients with node negative T1c, triple negative breast cancer. Seung Taek Lim, Chan Heun Park, +7 authors, Young Jin Suh. less PLoS One, 2018 May 17; 13(5). PMID: 29768496 Free PMC article.
Accuracy of a nomogram to predict the survival benefit of surgical axillary staging in T1 breast cancer patients. Yuxia Chen, Yuanqi Zhang, +4 authors, Xiang Chen. less Medicine (Baltimore), 2018 Jun 29; 97(26). PMID: 29953003 Free PMC article.
KDM4B-regulated unfolded protein response as a therapeutic vulnerability in PTEN-deficient breast cancer. Wenyu Wang, Gokce Oguz, +5 authors, Qiang Yu. less J Exp Med, 2018 Sep 30; 215(11). PMID: 30266800 Free PMC article.
Would 1.0 cm be a more suitable cutoff to subdivide pT1 tumors in hormone receptor-negative and HER2-positive breast cancer? Changjun Wang, Yidong Zhou, +9 authors, Qiang Sun. less Cancer Med, 2018 Oct 03; 7(11). PMID: 30277006 Free PMC article.
Comprehensive identification and characterization of somatic copy number alterations in triple‑negative breast cancer. Zaibing Li, Xiao Zhang, +6 authors, Ning Huang. less Int J Oncol, 2020 Jan 03; 56(2). PMID: 31894314 Free PMC article.
Assessing the impact of the addition of dendritic cell vaccination to neoadjuvant chemotherapy in breast cancer patients: A model-based characterization approach. Belén P Solans, Ascensión López-Díaz de Cerio, +7 authors, Marta Santisteban. less Br J Clin Pharmacol, 2019 Apr 02; 85(8). PMID: 30933365 Free PMC article.
Cost-effectiveness of adjuvant paclitaxel and trastuzumab for early-stage node-negative, HER2-positive breast cancer. Ali Hajjar, Mehmet A Ergun, Oguzhan Alagoz, Murtuza Rampurwala. PLoS One, 2019 Jun 06; 14(6). PMID: 31166995 Free PMC article.
Regulation of Hippo signaling and triple negative breast cancer progression by an ubiquitin ligase RNF187. Zhonghao Wang, Qiong Kong, +20 authors, Ting Zhuang. less Oncogenesis, 2020 Mar 22; 9(3). PMID: 32198343 Free PMC article.
Do 21-Gene Recurrence Score Influence Chemotherapy Decisions in T1bN0 Breast Cancer Patients? Jing Yu, Jiayi Wu, +6 authors, Kunwei Shen. less Front Oncol, 2020 Jun 02; 10. PMID: 32477946 Free PMC article.
Association of Endocrine Therapy With Overall Survival in Women With Small, Hormone Receptor-Positive, ERBB2-Negative Breast Cancer. Sung Jun Ma, Oluwadamilola T Oladeru, Anurag K Singh. JAMA Netw Open, 2020 Aug 25; 3(8). PMID: 32833014 Free PMC article.
Transcriptomic analyses identify key differentially expressed genes and clinical outcomes between triple-negative and non-triple-negative breast cancer. Bo Chen, Hailin Tang, +4 authors, Ning Liao. less Cancer Manag Res, 2019 Jan 08; 11. PMID: 30613165 Free PMC article.
Construction of prognostic microRNA signature for human invasive breast cancer by integrated analysis. Wei Shi, Fang Dong, +7 authors, Tao Huang. less Onco Targets Ther, 2019 Apr 03; 12. PMID: 30936717 Free PMC article.
Association of Adjuvant Chemotherapy With Overall Survival Among Women With Small, Node-Negative, Triple-Negative Breast Cancer. Oluwadamilola T Oladeru, Anurag K Singh, Sung Jun Ma. JAMA Netw Open, 2020 Sep 15; 3(9). PMID: 32926113 Free PMC article.
Progress: Targeted Therapy, Immunotherapy, and New Chemotherapy Strategies in Advanced Triple-Negative Breast Cancer. Jinhong Shi, Feiqi Liu, Yanqiu Song. Cancer Manag Res, 2020 Oct 17; 12. PMID: 33061626 Free PMC article. Review.
Management of Breast Cancer During the COVID-19 Pandemic: A Stage- and Subtype-Specific Approach. Jennifer Y Sheng, Cesar A Santa-Maria, +18 authors, Karen L Smith. less JCO Oncol Pract, 2020 Jul 01; 16(10). PMID: 32603252 Free PMC article.
Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies. Gagan K Gupta, Amber L Collier, +13 authors, Amy H Tang. less Cancers (Basel), 2020 Aug 28; 12(9). PMID: 32846967 Free PMC article. Review.
Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. Sara M Tolaney, Hao Guo, +23 authors, Eric P Winer. less J Clin Oncol, 2019 Apr 03; 37(22). PMID: 30939096 Free PMC article. Highly Cited.
The Survival Outcomes of T1aN0M0 Triple-Negative Breast Cancer With Adjuvant Chemotherapy. Wen-Fen Fu, Qing-Xia Chen, +2 authors, Xiao-Xiao Wang, Jie Zhang, Chuan-Gui Song. less Front Oncol, 2020 Oct 27; 10. PMID: 33102205 Free PMC article.
The ubiquitin ligase RNF181 stabilizes ERα and modulates breast cancer progression. Jian Zhu, Xin Li, +3 authors, Peng Su, Min Xue, Yifeng Zang, Yinlu Ding. less Oncogene, 2020 Sep 26; 39(44). PMID: 32973333 Free PMC article.
Evaluation of Adjuvant Treatments for T1 N0 M0 Triple-Negative Breast Cancer. Zhen Zhai, Yi Zheng, +12 authors, Zhijun Dai. less JAMA Netw Open, 2020 Nov 20; 3(11). PMID: 33211105 Free PMC article.
Omitting Adjuvant Radiotherapy for Hormone Receptor‒Positive Early-Stage Breast Cancer in Old Age: A Propensity Score Matched SEER Analysis. Yi-Jun Kim, Kyung Hwan Shin, Kyubo Kim. Cancer Res Treat, 2018 May 12; 51(1). PMID: 29747486 Free PMC article.
SEOM clinical guidelines in early stage breast cancer (2018). F Ayala de la Peña, R Andrés, +7 authors, E Ciruelos. less Clin Transl Oncol, 2018 Nov 18; 21(1). PMID: 30443868 Free PMC article.
TRIM3 inhibits P53 signaling in breast cancer cells. Xinxing Wang, Yujie Zhang, +4 authors, Dongwei Dou. less Cancer Cell Int, 2020 Dec 10; 20(1). PMID: 33292295 Free PMC article.
Multiple Microinvasion Foci in Ductal Carcinoma In Situ Is Associated With an Increased Risk of Recurrence and Worse Survival Outcome. Jing Si, Rong Guo, +7 authors, Caiping Chen. less Front Oncol, 2020 Dec 22; 10. PMID: 33344258 Free PMC article.
Survival Outcome and Impact of Chemotherapy in T1 Node-Negative Triple-Negative Breast Cancer: A SEER Database Analysis. Jingyi Zhang, Wenna Wang, +5 authors, Ying Fan. less J Oncol, 2021 Jan 01; 2020. PMID: 33381180 Free PMC article.
Clinical significance of HER2 status in T1bN0 breast cancer: a nationwide study from the Korean Breast Cancer Society. Young-Joon Kang, Se Jeong Oh, +9 authors, Yong-Seok Kim. less Breast Cancer Res Treat, 2021 Jan 04;. PMID: 33389401
The role of chemotherapy in patients with T1bN0M0 triple-negative breast cancer: a real-world competing risk analysis. Tian Lan, Yunyan Lu, +4 authors, Zujian Hu. less J Cancer, 2021 Jan 05; 12(1). PMID: 33391398 Free PMC article.
Long-Term Prognostication for 20 114 Women With Small and Node-Negative Breast Cancer (T1abN0). David Jaraj, Jonas Höijer, +9 authors, Pettersson Andreas. less JNCI Cancer Spectr, 2021 Jan 15; 5(1). PMID: 33442658 Free PMC article.
De-escalated Therapy Omitting Anthracyclines for Stage I HER2-positive Breast Cancer: A Retrospective Observational Study. Shogo Nakamoto, Masahiko Ikeda, +2 authors, Shinichiro Kubo, Mari Yamamoto, Tetsumasa Yamashita. less In Vivo, 2020 Nov 05; 34(6). PMID: 33144488 Free PMC article.

BioKDE: Biomedical Knowledge Discovery Engine

Abstract

Other Links